What we do
Revlar Diagnostics will disrupt the market in Diagnostic Testing for Infectious Diseases by developing an array of low-cost, easy-to-use diagnostic products. We are utilizing novel molecular switch technology to produce instant, reliable, and highly accurate test results for a variety of markets, including:
The first two tests being developed are for detecting and reporting the presence of COVID-19 and its variants, and Influenza A & B.
President and Chief Operating Officer
Mr. Williams, who has a strong background both in business operations and data management, joined Revlar to lead our information collection and reporting to the FDA and other agencies, as well as development of apps linked to our tests for use by lab personnel and consumers. He has held senior positions with Cadence Design Systems and Synopsys, and founded Ladera Labs, a hardware and software company. He earned an MS in Electrical Engineering from the University of South Florida, and an MS in Management from Stanford University’s Graduate School of Business.
Madeline Murphy, PhD
Madeline Murphy, Ph.D. is a Conway Fellow and Principal Investigator in the School of Medicine, UCD. She leads a translational medical research group within the Conway Institute translating her research findings towards development of innovative diagnostics and therapeutics. She leads the synthesis and validation molecular biology work in the UCD-Revlar Collaboration.
Dr. Hannah Rushe
Dr. Hannah Rushe is a protein engineer and Principal Investigator who is passionate about the development of novel therapeutics and diagnostics. Hannah holds a PhD from the Royal College of Surgeons in Ireland, where she worked on a novel therapeutic for the treatment of haemophila. She won the RCSI innovation award for her contribution to the development of the therapeutic and the filing of the patent. At the University College Dublin, she works on the development of diagnostic tests which are fast, highly sensitive and accurate. Here, Hannah’s role as a protein engineer is the production of the biological components of the diagnostics.
Dr. Yilin Wang
Dr. Yilin Wang is a clinical virologist and Principal Investigator whose scientific interests focus on the development of in-vitro diagnostic assays for infectious diseases. She holds a PhD from the University of Helsinki, Finland and a Master of Medical Science from the University of Uppsala, Sweden. During her doctoral research in the laboratory of Professor Klaus Hedman, she developed innovative multiplex methods for the detection of viral infections. At the University College Dublin she works on the development of diagnostic tests which are fast, highly sensitive and accurate. Here, the aim is to detect multiple infections in a single point-of-care format.
Mike Klass, PhD
Chief Science Officer
Dr. Klass has more than 30 years of experience in bringing leading-edge biological products to market. He’s been a key contributor to the success of molecular diagnostic tests – including obtaining FDA approval – for Abbott Labs, Gen-Probe, CARIS Life Systems and other companies. He has expertise in strategic planning, intellectual property, product design, product development, and manufacturing. He is a graduate of the University of Wisconsin, received his Ph.D. in Cell Biology from the University of Wyoming, did postdoctoral work in genetics at the University of Colorado at Boulder, and early in his career was a tenured professor of biology at the University of Houston. He holds 25 US patents, and has published 30 scientific papers.
Thayne Larson, M.D.
Chief Medical Officer
Dr. Larson is a researcher and practitioner affiliated with the Mayo Clinic-Scottsdale, a principal investigator for FDA trials, the author of more than 80 research papers, and has advised Boston Scientific, Allergan, Johnson & Johnson, Medtronic, Endocare, ProCarrier Drug Co., the Institute of Medical Research, and other companies. He is an Associate Professor at the Mayo Graduate School of Medicine, and is a Clinical Lecturer at University of Arizona College of Medicine. He did his undergraduate work at Brigham Young University, where he received a Presidential Scholarship, and earned his M.D. at Louisiana State University Medical School. He holds a U.S. patent on a medical treatment technology.
Dr. Jim Sackrison
Dr. Jim Sackrison is an Adjunct Professor at the UCD School of Physics. He is a Senior Development Manager in the medical device industry with over 50 IVD products. At UCD he leads the integration and translation work of the UCD molecular switch sensor into industry standard diagnostic assays. Jim has over 30 years experience in the diagnostic industry including as Principal Scientist of Beckman/Danaher.
Donal MacKernan, PhD
Donal MacKernan, Ph.D. of the UCD School of Physics is the Principal Investigator and Inventor of the UCD Molecular sensor and is the overall leader of the multidisciplinary UCD team in the UCD-REVLAR research collaboration. He focuses on the design and optimization of diagnostic sensors using advanced computer simulation. He is also director of CECAM-IRL, the Irish node of CECAM (Centre Européen de Calcul Atomique et Moléculaire), an organization devoted to the promotion of advanced computational methods in science and technology.